title: The progress of immunotherapy for glioblastoma.
abstract: Glioblastoma is the most common primary brain tumor in adults, accounting for about half of all primary brain tumors. Despite multiple therapeutic interventions such as surgical resection, radiotherapy, and systemic chemotherapy, the prognosis for glioblastoma remains poor. Due to the scientific community's enhanced understanding of the CNS immune system and significant achievements in tumor immunotherapy in recent years, immunotherapy has become a promising GBM treatment. In vaccine therapy, a number of clinical trials have achieved encouraging results. In antibody therapy, antibodies are used to target immune checkpoints such as ipilimumab and nivolumab. Bioengineering technology has also lead to a new field of tumor immunotherapy, whereby genetically modified tumor-specific T cells are reintroduced into a patient's body.
authors: a Department of Neurosurgery ; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ; Beijing , China.
authors: Qiangyi
authors: Q
authors: Zhou
authors: a Department of Neurosurgery ; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ; Beijing , China.
authors: Yu
authors: Y
authors: Wang
authors: a Department of Neurosurgery ; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ; Beijing , China.
authors: Wenbin
authors: W
authors: Ma
mesh_terms: D002986:Clinical Trials as Topic; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016896:Treatment Outcome
keywords: adoptive immunotherapy; glioblastoma; immune checkpoint; immunotherapy; vaccine